☆ 4.7 Review

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

MOLECULAR CANCER (2022)

Related references

Note: Only part of the references are listed.
Article Gastroenterology & Hepatology

Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy

Jumin Huang et al.

Summary: This study demonstrated that the combination of GPs and alpha PD-1 mAb enhanced the antitumor response by modulating gut microbiota. The GPs increased microbial metabolites and reshaped gut microbiota towards responders, sensitizing non-small cell lung cancer patients to anti-PD-1 immunotherapy. Additionally, gut microbiota could serve as a novel biomarker to predict the response to anti-PD-1 immunotherapy.

GUT (2022)

Add to Collection
Review Pharmacology & Pharmacy

Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials

Yihui Song et al.

Summary: Phosphorylation, regulated by phosphorylase and dephosphorylase, is a reversible post-translational modification mediating important cellular events. SHP2, as an oncogenic protein in the protein tyrosine phosphatases family, plays crucial roles in multiple cascade signaling pathways. Dysregulation of SHP2 contributes to the pathogenesis of different cancers, making it a promising therapeutic target.

PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection
Article Oncology

JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer

Suresh S. Ramalingam et al.

Summary: The combination of niraparib and pembrolizumab showed promising clinical activity in patients with advanced and/or metastatic NSCLC, with significant objective response rates observed in patients with high levels of PD-L1 expression. This combination therapy also demonstrated manageable safety profiles consistent with the known side effects of each drug individually, supporting further investigation into its potential as a treatment option.

CANCER (2022)

Add to Collection
Article Oncology

Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity

Yan Wang et al.

Summary: The newly designed CD47/PD-L1 bispecific antibody, IBI322, effectively inhibits CD47-SIRP alpha signal, promotes tumor cell phagocytosis, accumulates in PD-L1-positive tumors, shows synergistic therapeutic effects, and has minimal impact on red blood cells, making it a promising option for cancer treatment.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection
Review Pharmacology & Pharmacy

Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies

Zhendong Song et al.

Summary: SHP2 is a significant target for various diseases, serving as an oncogenic phosphatase in cancers. Recent discoveries of potent allosteric inhibitors have shown potential in treating solid tumors.

ACTA PHARMACEUTICA SINICA B (2021)

Add to Collection
Editorial Material Immunology

Manganese enhances the antitumor function of CD8+ T cells by inducing type I interferon production

Yuan Song et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2021)

Add to Collection
Article Oncology

Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma

Nan Xiao et al.

Summary: This study found that Siglec-10(hi) TAMs in HCC patients are associated with immune suppression and poor prognosis. Blocking Siglec-10 can enhance the anti-tumor effects of CD8(+) T cells and improve the efficacy of PD-1 inhibitors.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)

Add to Collection
Article Oncology

Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma

Sean McBride et al.

Summary: The study compared the efficacy of nivolumab alone versus nivolumab plus SBRT in treating patients with metastatic HNSCC, and found that the addition of SBRT did not improve treatment response in unselected patients.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection
Article Oncology

Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

Matthew D. Hellmann et al.

Summary: The study aimed to investigate the safety and efficacy of the TIM-3/PD-L1 bispecific antibody LY3415244 in patients with advanced solid tumors. Unexpected immunogenicity targeting both arms of the bispecific antibody led to early study termination. Overall, the bispecific antibody showed unexpected phenomena in terms of preexisting ADAs and immunogenicity.

CLINICAL CANCER RESEARCH (2021)

Add to Collection
Article Chemistry, Medicinal

Recent advances of dual FGFR inhibitors as a novel therapy for cancer

Qi Liang et al.

Summary: FGFR, a crucial receptor tyrosine kinase, is associated with various tumors. Although numerous anti-cancer drugs targeting FGFR have been developed, single-target drugs are prone to drug resistance, making research on dual-target inhibitors a current hot topic.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)

Add to Collection
Review Oncology

MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma

Daniel V. T. Catenacci et al.

Summary: This study describes the design and rationale of a clinical trial evaluating the use of margetuximab plus retifanlimab or margetuximab plus tebotelimab in unresectable metastatic/locally advanced gastric/gastroesophageal junction adenocarcinoma as first-line therapy. Primary endpoints include objective response rate, overall survival, and safety/tolerability.

FUTURE ONCOLOGY (2021)

Add to Collection
Review Oncology

Regulation of PD-L1 expression in the tumor microenvironment

Ming Yi et al.

Summary: PD-L1 expression is regulated by various factors, impacting the treatment effect and patient selection. Understanding the mechanisms of PD-L1 regulation helps enhance the efficacy of immunotherapy.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection
Article Gastroenterology & Hepatology

CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma

Laurence P. Diggs et al.

Summary: Stimulating antigen-presenting cells such as macrophages and dendritic cells through CD40 agonist significantly enhances the response to anti-PD-1 therapy in intrahepatic cholangiocarcinoma (iCCA) models, leading to a greater reduction in tumor burden. The combination of CD40 agonist and PD-1 inhibitor, along with chemotherapy, shows promising results in improving therapeutic efficacy and overall survival.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection
Review Medicine, General & Internal

Enhancing anti-tumour efficacy with immunotherapy combinations

Funda Meric-Bernstam et al.

Summary: This article evaluates immune therapy response biomarkers to identify patients who benefit from monotherapy rather than combination therapy. It also reviews the rationale and strategies for combination therapy, including combinations with chemotherapy, targeted therapy, and other immunomodulators.

LANCET (2021)

Add to Collection
Article Medicine, General & Internal

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Paul Baas et al.

Summary: Nivolumab plus ipilimumab demonstrated significant improvement in overall survival compared to standard chemotherapy for unresectable malignant pleural mesothelioma. This first-in-class treatment regimen has been approved for previously untreated patients in the USA and showed promising outcomes with manageable adverse events.

LANCET (2021)

Add to Collection
Article Oncology

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman et al.

Summary: The study showed that first-line treatment with durvalumab plus platinum-etoposide resulted in sustained improvement in overall survival, while the addition of tremelimumab to this combination did not significantly enhance efficacy. These findings support the use of durvalumab plus platinum-etoposide as a new standard of care for extensive-stage small-cell lung cancer.

LANCET ONCOLOGY (2021)

Add to Collection
Article Oncology

The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated Immunotherapies

Sruthy Varghese et al.

Summary: Immune-checkpoint inhibitors and TIL therapies have improved survival in melanoma patients, but many do not respond. Combinations with novel therapies show potential to enhance patient responses.

MOLECULAR CANCER THERAPEUTICS (2021)

Add to Collection
Article Multidisciplinary Sciences

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

Erez N. Baruch et al.

Summary: This study conducted a phase 1 clinical trial and found that FMT treatment in patients with anti-PD-1-refractory metastatic melanoma, along with reinduction of anti-PD-1 immunotherapy, resulted in clinical responses in some patients. This suggests that modulating the gut microbiota could be a promising approach in cancer treatment.

SCIENCE (2021)

Add to Collection
Article Oncology

Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells

Simon J. Dovedi et al.

Summary: MEDI5752 is a novel monovalent bispecific antibody that enhances the clinical benefits of PD-1 blockade while reducing immune-related adverse events, leading to improved therapeutic outcomes. It represents a significant advancement in the rational design of cancer immunotherapy and shows promising potential in targeting PD-1(+) T cells with enhanced activity compared to conventional mAb combination strategies.

CANCER DISCOVERY (2021)

Add to Collection
Article Multidisciplinary Sciences

SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms

Ye Wang et al.

Summary: The study unveiled a new immune modulatory function of SHP2, with inhibition promoting anti-tumor immunity by enhancing T cell cytotoxicity and immune-mediated tumor regression. Additionally, SHP2 inhibition improved responses to anti-PD-1 blockade, suggesting its potential as a promising strategy for cancer immunotherapy.

SCIENTIFIC REPORTS (2021)

Add to Collection
Article Critical Care Medicine

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Caicun Zhou et al.

Summary: The study showed a statistically significant and clinically meaningful improvement in progression-free survival with camrelizumab plus chemotherapy compared to chemotherapy alone, making it a promising first-line treatment option for Chinese patients with advanced non-squamous NSCLC without EGFR and ALK alterations, with further long-term outcomes and confirmatory testing still ongoing.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection
Review Oncology

Combination strategies to maximize the benefits of cancer immunotherapy

Shaoming Zhu et al.

Summary: This review discusses the relationship between cancer immune response and resistance mechanisms to immunotherapy, as well as provides a comprehensive overview of the latest clinical status and FDA-approved combination therapies. It also covers therapies targeting cytokines, immunotherapy, virotherapy, innate immune modifiers, and cancer vaccines, as well as insights from the 2020 China Immuno-Oncology Workshop.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection
Review Oncology

Cancer-associated adipocytes as immunomodulators in cancer

Qi Wu et al.

Summary: CAAs play important roles in the tumor-adipose microenvironment, influencing treatment outcomes by interacting with the immune response and cancer.

BIOMARKER RESEARCH (2021)

Add to Collection
Article Oncology

A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis

A. Brufsky et al.

Summary: The study evaluated the effectiveness of using cobimetinib plus chemotherapy, with or without the programmed death-ligand 1 inhibitor atezolizumab, in patients with locally advanced or mTNBC. The results showed that the addition of cobimetinib to paclitaxel did not significantly increase progression-free survival or objective response rate, but demonstrated potential activity in this difficult-to-treat population.

ANNALS OF ONCOLOGY (2021)

Add to Collection
Article Oncology

Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody

James J. Harding et al.

Summary: The study evaluated the safety and effectiveness of the TIM-3 monoclonal antibody LY3321367 in patients with advanced solid tumors and determined the recommended dosage. Results showed that LY3321367 had acceptable safety and favorable pharmacokinetics, but only modest antitumor activity.

CLINICAL CANCER RESEARCH (2021)

Add to Collection
Article Oncology

TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells

Liang Mao et al.

Summary: This study found that CD155 and PD-L1 are highly co-expressed on MDSCs in HNSCC patients, and the combined blockade of TIGIT/CD155 and PD-1/PD-L1 signaling significantly inhibited tumor growth in mouse models, enhanced the percentage of effector T cells, and induced immune memory effects.

ORAL ONCOLOGY (2021)

Add to Collection
Article Oncology

The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

Ming Yi et al.

Summary: The bispecific antibody YM101 can simultaneously target the TGF-beta and PD-L1 pathways, demonstrating superior anti-tumor efficacy. YM101 enhances the anti-tumor immune response by increasing the numbers of tumor infiltrating lymphocytes and dendritic cells, elevating the ratio of M1/M2, and enhancing cytokine production in T cells.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection
Review Oncology

FGFR-TKI resistance in cancer: current status and perspectives

Sitong Yue et al.

Summary: This review discusses the mechanisms of resistance to FGFR-TKI in cancer and strategies to overcome resistance, including gatekeeper mutations, alternative signaling pathway activation, lysosome-mediated TKI sequestration, and gene fusion. Potential strategies to overcome resistance include developing covalent inhibitors, dual-target inhibitors, combination therapy, and targeting lysosomes to transition to precision medicine and individualized treatment.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection
Review Pharmacology & Pharmacy

Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS

Robert Roskoski

Summary: RAS proteins play crucial roles in physiological signal transduction processes related to cell growth, division, and survival. RAS mutations, especially KRAS mutations, are common in various cancers, with potential implications for targeted therapy. Covalent modification of the KRAS C12 led to the discovery of a new pocket, facilitating the development of second-line treatment for KRAS(G12C)-mutant non-small cell lung cancer. Efforts are also being made to develop inhibitors targeting MAP kinase and PI3-kinase pathways as indirect RAS antagonists.

PHARMACOLOGICAL RESEARCH (2021)

Add to Collection
Article Oncology

Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial

Yun Fan et al.

Summary: The study demonstrated potential antitumor activity of camrelizumab plus apatinib in patients with ED-SCLC who had failed platinum-based chemotherapy, including those who were chemotherapy-sensitive and chemotherapy-resistant. Treatment-related adverse events of grade 3 or higher were reported in a significant proportion of patients, leading to treatment discontinuation in some cases. Further clinical studies are warranted to explore the efficacy of this combination therapy in SCLC.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection
Article Medicine, General & Internal

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

T. K. Choueiri et al.

Summary: The study demonstrates that nivolumab plus cabozantinib has significant advantages over sunitinib in the treatment of previously untreated advanced renal-cell carcinoma, including progression-free survival, overall survival, and likelihood of response.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection
Article Multidisciplinary Sciences

Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients

Diwakar Davar et al.

Summary: The study demonstrated that fecal microbiota transplantation combined with anti-PD-1 therapy can overcome resistance to anti-PD-1 in a subset of PD-1 refractory melanoma patients, leading to clinical benefits. This approach induced changes in the gut microbiome and reprogrammed the tumor microenvironment, ultimately enhancing the efficacy of anti-PD-1 treatment.

SCIENCE (2021)

Add to Collection
Review Oncology

Tumor and Systemic Immunomodulatory Effects of MEK Inhibition

Lauren Dennison et al.

Summary: MEK inhibitors, as a potential therapy in combination with systemic immunotherapies, have the ability to reprogram the tumor microenvironment to enhance anti-tumor immunity. However, recent clinical studies have yielded mixed results, underscoring the need for further validation.

CURRENT ONCOLOGY REPORTS (2021)

Add to Collection
Article Oncology

Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer

Tian Zhang et al.

Summary: The study found that CTCs from men with mPC often express B7-H3, and there is heterogeneity in the expression of immune checkpoints PD-L1, PD-L2, and CTLA-4 across different disease states. Detection of these immune checkpoints in CTCs may aid in monitoring immunotherapy efficacy.

BIOMARKER RESEARCH (2021)

Add to Collection
Article Oncology

A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer

A. J. R. McGray et al.

Summary: Cancer immunotherapies have shown significant clinical responses in some ovarian cancer patients, but there is still a need to identify combination therapies to overcome limitations of single-agent treatments. A study using a pre-clinical model of aggressive ovarian cancer found that a heterologous prime/boost cancer vaccine combined with checkpoint blockade improved tumor control, with a focus on the essential role of CD8 + T cells in tumor regression.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection
Article Oncology

Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano et al.

Summary: The study aimed to evaluate the safety and efficacy of Sabatolimab and spartalizumab in patients with advanced solid tumors. The results showed that the combination of Sabatolimab plus spartalizumab was well tolerated and showed signs of antitumor activity, with the recommended dose for Sabatolimab being 800 mg Q4W, with or without 400 mg spartalizumab Q4W.

CLINICAL CANCER RESEARCH (2021)

Add to Collection
Review Oncology

Novel therapies emerging in oncology to target the TGF-β pathway

Byung-Gyu Kim et al.

Summary: The TGF-beta signaling pathway plays a crucial role in physiological cellular processes and is dysregulated in pathologies such as cancer. It can function as either a tumor promoter or a tumor suppressor, affecting processes such as cell proliferation, migration, invasion, metastasis, and immunosurveillance. Various therapeutic strategies targeting TGF-beta signaling have shown promise in preclinical studies and clinical trials, but challenges remain in balancing its tumor-promoting and tumor-suppressing activities for effective cancer treatment.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection
Review Oncology

Immunotherapies targeting stimulatory pathways and beyond

Julian A. Marin-Acevedo et al.

Summary: Co-stimulatory and co-inhibitory molecules are crucial in T cell function. Immunotherapy targeting inhibitory molecules has shown durable responses in some patients, while targeting stimulatory pathways on immune cells is another strategy to enhance anti-tumor activities.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection
Review Oncology

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?

Meng Qiao et al.

Summary: Although ICIs have significantly changed the treatment paradigm in advanced NSCLC, their clinical benefits are limited in patients with EGFR-mutated tumors due to the unique characteristics of the tumor microenvironment. The cancer immunogram can visualize the state of cancer-immune system interactions in EGFR-mutated NSCLC, helping identify subpopulations that may benefit from ICI treatment. Future strategies need to be developed to maximize the efficacy of ICI treatment in patients with EGFR-mutated NSCLC in the era of combination immunotherapies.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection
Article Oncology

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

Tianqing Chu et al.

Summary: Although the evidence supporting the combination of immune checkpoint inhibitors and antiangiogenic tyrosine kinase inhibitors in treatment-naive patients with advanced NSCLC is insufficient, this report presented the efficacy and safety of sintilimab combined with anlotinib in a phase 1b trial. The study showed promising results with a high objective response rate and disease control rate, as well as manageable treatment-related adverse events.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection
Article Oncology

Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial

Nasser K. Altorki et al.

Summary: The combination of neoadjuvant durvalumab and stereotactic body radiotherapy in early-stage NSCLC patients shows a high major pathological response rate and is well tolerated, suggesting its potential in treatment, although it comes with certain adverse events.

LANCET ONCOLOGY (2021)

Add to Collection
Article Oncology

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Nancy Y Lee et al.

LANCET ONCOLOGY (2021)

Add to Collection
Review Oncology

Roles of the intestinal microbiota and microbial metabolites in acute GVHD

Dandan Lin et al.

Summary: The intestinal microbiota plays a crucial role in the pathogenesis of acute GVHD, with dysbiosis associated with poor prognosis. Intervention strategies targeting the microbiota, such as antibiotics, prebiotics, probiotics, postbiotics, and fecal microbiota transplantation, are potential new treatment options for acute GVHD.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)

Add to Collection
Article Multidisciplinary Sciences

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers

David H. Peng et al.

Summary: Understanding the resistance mechanisms in mutant KRAS lung cancers to targeted therapies and immune checkpoint blockade is crucial for developing novel combination therapies. MEK inhibition combined with anti-PD-L1 can synergistically reduce lung tumor growth, but resistance may develop eventually. Increased Th17 cell infiltration in resistant tumors promotes invasiveness and resistance to MEK inhibitors, and a triple therapy targeting MEK, PD-L1, and IL-17 may overcome this resistance for better in vivo responses.

NATURE COMMUNICATIONS (2021)

Add to Collection
Article Multidisciplinary Sciences

PD-1 suppresses TCR-CD8 cooperativity during T-cell antigen recognition

Kaitao Li et al.

Summary: The study reveals that PD-1 inhibits the cooperative interaction between TCR-pMHC-CD8 by suppressing TCR proximal signaling, leading to reduced antigen recognition by T cells.

NATURE COMMUNICATIONS (2021)

Add to Collection
Review Immunology

Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma

Emily J. Lelliott et al.

Summary: The recent development of targeted and immune-based therapies has revolutionized melanoma treatment, with ongoing exploration of combination therapies. The combination of BRAF, MEK, and CDK4/6 inhibitors holds promise for new treatment approaches, while immunotherapy is increasingly being utilized in melanoma patients.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection
Review Immunology

Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment

Morgane Bourhis et al.

Summary: VEGF-A plays a central role in tumor angiogenesis and is also an immunosuppressive factor, modulating immune cells and affecting regulatory T cells. Anti-angiogenic agents targeting VEGF-A/VEGFR can limit tumor-induced immunosuppression and enhance treatment efficacy.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection
Article Oncology

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer A Phase 3 Randomized Clinical Trial

Jie Wang et al.

Summary: This study showed that tislelizumab combined with chemotherapy can significantly improve progression-free survival in patients with advanced squamous non-small-cell lung cancer, providing potential benefits in clinical practice.

JAMA ONCOLOGY (2021)

Add to Collection
Meeting Abstract Oncology

Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer

Y. Janjigian et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection
Article Oncology

The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors

Reid P. Bissonnette et al.

Summary: HBI-8000, as a novel oral HDAC inhibitor, enhances anti-tumor activity and reprograms the tumor microenvironment to be more responsive to ICIs, suggesting potential for combination therapy in clinics.

BMC CANCER (2021)

Add to Collection
Article Oncology

Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors

Antoine Hollebecque et al.

Summary: The study evaluated the safety and efficacy of anti-PD-L1 antibody LY3300054 monotherapy or in combination with anti-TIM-3 antibody LY3321367 in patients with MSI-H/dMMR advanced solid tumors. Both regimens showed promising clinical activity against PD-1/PD-L1 inhibitor-naive MSI-H/dMMR tumors, with the combination having limited clinical benefit in patients with PD-1/PD-L1 inhibitor-resistant/refractory MSI-H/dMMR tumors.

CLINICAL CANCER RESEARCH (2021)

Add to Collection
Article Oncology

A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1

Sarah A. Weiss et al.

Summary: This first in-human study of patients with anti-PD-1/PD-Li-resistant tumors treated with dual macrophage polarizing therapy, with or without nivolumab, demonstrated safety and pharmacodynamic activity. Further optimization of the dosing frequency and sequence of this combination is warranted.

CLINICAL CANCER RESEARCH (2021)

Add to Collection
Article Biochemistry & Molecular Biology

The biology of combination immunotherapy in recurrent metastatic head and neck cancer

Xun Yuan et al.

Summary: The development of immune checkpoint inhibitors has revolutionized treatment for head and neck cancer, but patients often exhibit primary resistance to immunotherapy. Ongoing trials are exploring combinations of immunotherapy with other interventions to improve treatment outcomes. As novel strategies are leveraged, the significance of immunotherapy in recurrent/metastatic head and neck cancer is being further revealed.

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2021)

Add to Collection
Meeting Abstract Oncology

COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716).

Daniel A. Vaena et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection
Meeting Abstract Oncology

A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies.

Manish R. Patel et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection
Meeting Abstract Oncology

Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.

Cristina Suarez Rodriguez et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection
Meeting Abstract Oncology

Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-beta, in patients with advanced solid tumors.

Dan Liu et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection
Article Oncology

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Robin Kate Kelley et al.

Summary: This study evaluated the treatment regimens for patients with hepatocellular carcinoma and found that all regimens were tolerable and clinically active, with the T300 + D regimen showing the most favorable benefit-risk profile. Early expansion of CD8+ lymphocytes was associated with treatment response across arms.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection
Meeting Abstract Oncology

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).

Evan J. Lipson et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection
Article Oncology

Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors

Yangyang Li et al.

Summary: The study found that PVRIG blockade could slow tumor growth and prolong survival in mice by inhibiting exhaustion of NK cells and CD8(+) T cells. Combined blockade of PVRIG and PD-L1 showed better efficacy in controlling tumor growth. These results highlight the importance of NK cells and provide insights for clinical application of PVRIG-targeted drugs.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection
Article Oncology

Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers

Ming Yi et al.

Summary: Combining bivalent manganese (Mn2+) with the anti-TGF-beta/PD-L1 bispecific antibody YM101 enhances cancer antigen presentation, activates innate and adaptive immunity, and shifts the tumor microenvironment from immune-excluded or immune-desert to immune-inflamed, resulting in a potent and broad antitumor effect.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection
Article Oncology

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Shun Lu et al.

Summary: The addition of tislelizumab to chemotherapy in patients with advanced nonsquamous NSCLC resulted in significantly prolonged progression-free survival (PFS), higher response rates, and longer response duration compared with chemotherapy alone, indicating a promising new option for first-line treatment regardless of disease stage.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection
Article Oncology

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

Caicun Zhou et al.

Summary: A randomized, double-blind, phase 3 study found that Sintilimab plus GP showed better progression-free survival compared to GP alone in first-line treatment for patients with locally advanced or metastatic sqNSCLC. The toxicity of the treatment was acceptable, and no new unexpected safety signals were observed.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection
Article Medicine, General & Internal

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Jong-Mu Sun et al.

Summary: This study aimed to evaluate the antitumor activity of pembrolizumab plus chemotherapy versus chemotherapy alone as first-line treatment in advanced esophageal cancer. Results showed that pembrolizumab plus chemotherapy significantly improved overall survival and progression-free survival in patients with esophageal squamous cell carcinoma.

LANCET (2021)

Add to Collection
Article Oncology

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study

Zhenggang Ren et al.

Summary: The study aimed to assess the efficacy of sintilimab plus IBI305 versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma in China, showing significant overall survival and progression-free survival benefits with acceptable safety profiles.

LANCET ONCOLOGY (2021)

Add to Collection
Review Oncology

Synthetic Lethality in Ovarian Cancer

Akshaya Chandrasekaran et al.

Summary: This article summarizes key information on overcoming chemoresistance in ovarian cancer using synthetic lethality strategies, including the biological rationale and clinical evaluation of targeting BRCA-PARP synthetic lethality. In addition, it also discusses how to apply synthetic lethality strategies in non-BRCA mutant cancers, along with the combination of PARP inhibitors and other methods to target ovarian cancer.

MOLECULAR CANCER THERAPEUTICS (2021)

Add to Collection
Review Biochemistry & Molecular Biology

HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence

Jianjiang Fu et al.

Summary: This review comprehensively explores the role of the HGF/c-MET signaling pathway in cancers, highlighting its influence on cellular processes, genomic characterization in carcinogenesis, and malignant biological behaviors. Although monotherapy targeting HGF/c-MET has shown limited clinical efficacy in most cancers, the major challenge in the future lies in exploring more options of combinational targeted therapy in cancers.

ONCOGENE (2021)

Add to Collection
Article Cell Biology

Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects

Adriana Petrazzuolo et al.

Summary: Immunogenic cell death (ICD) increases the immunogenicity of dying cells through a series of changes, and specific ALK inhibition may induce ICD in ALCL, stimulating the immune system and prolonging survival in cancer patients.

CELL DEATH & DISEASE (2021)

Add to Collection
Article Multidisciplinary Sciences

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma

Lars Ny et al.

Summary: The combination of HDAC inhibitor entinostat with anti-PD-1 antibody pembrolizumab shows durable responses in a subset of patients with metastatic uveal melanoma. Factors such as wildtype BAP1 gene, low tumor burden, and iris melanoma may be associated with better treatment response and longer survival.

NATURE COMMUNICATIONS (2021)

Add to Collection
Article Multidisciplinary Sciences

A human CD137xPD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade

Cecile Geuijen et al.

Summary: Researchers have discovered a human CD137xPD-L1 bispecific antibody, MCLA-145, which potently activates T cells at sub-nanomolar concentrations and demonstrates low systemic toxicity in non-human primates. The conditional activation of CD137 signaling by MCLA-145 may provide both safety and potency advantages, enhancing anti-cancer activity.

NATURE COMMUNICATIONS (2021)

Add to Collection
Article Oncology

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab

Prasad S. Adusumilli et al.

Summary: Regional delivery of mesothelin-targeted CAR T-cell therapy followed by pembrolizumab administration is safe, feasible, and demonstrates evidence of antitumor efficacy in patients with malignant pleural diseases. Our data support the investigation of combination immunotherapy with CAR T cells and PD-1 blockade agents in solid tumors.

CANCER DISCOVERY (2021)

Add to Collection
Article Chemistry, Multidisciplinary

Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD-L1 and CTLA-4

Chunjuan Jiang et al.

Summary: The development of a novel smart agent KN046@F-19-ZIF-8 improves the immune response rate of antibody drugs in tumor treatment and reduces toxic side effects, achieving excellent antitumor efficacy.

ADVANCED SCIENCE (2021)

Add to Collection
Article Oncology

Novel anti-4-1BBxPD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade

Seongju Jeong et al.

Summary: The novel anti-4-1BBxPD-L1 bispecific antibody, ABL503, shows promising biological activity in activating 4-1BB signaling in the context of PD-L1 and blocking PD-1/PD-L1 signaling. It enhances T-cell activation and reinvigorates tumor-infiltrating CD8(+) T cells, demonstrating superior anti-tumor activity with low risk of liver toxicity.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Article Oncology

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

Sarina A. Piha-Paul et al.

Summary: The study investigated the safety and efficacy of the antibody GWN323 in solid tumor patients. Results showed good tolerability of GWN323 as a single agent and in combination, with recommended doses of 1500mg q3w and GWN323 750 mg+spartalizumab 300mg q3w, respectively. Some treatment responses were observed in the combination arm.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Article Oncology

Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer

Tianhang Zhai et al.

Summary: A unique single-domain antibody targeting the CRD4 domain of 4-1BB was discovered in this study, which showed potent activation of 4-1BB and blockade of PD-L1 in cell-based assays. Incorporation of this antibody into a 4-1BB/PD-L1 bispecific (PM1003) resulted in potent inhibition of PD-L1 activity with minimal toxicity in vivo, making it a promising next generation therapeutic agent for cancer therapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Article Oncology

STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer

Seung Joon Lee et al.

Summary: STING activation can normalize the peritoneal vascular and immune microenvironment, converting immunologically cold peritoneal tumors into T-cell-inflamed tumors and providing a rationale for a novel combination therapeutic strategy for peritoneal carcinomatosis in colon cancer.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Article Oncology

Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis

Yvette Robbins et al.

Summary: In this study, dual PD-L1/TGF-b inhibition did not effectively inhibit papilloma growth in RRP patients and even increased the need for clinical interventions in some subjects post-treatment. TGF-b neutralization decreased proliferation within papillomas, indicating that intact TGF-b signaling restrains proliferation. Dual PD-L1/TGF-b inhibition did not enhance anti-HPV immunity within papillomas beyond what was observed with PD-L1 blockade.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Article Oncology

STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation

Takashi Nakamura et al.

Summary: STING-LNP treatment can overcome PD-1 resistance by activating NK cells, resulting in an increase in PD-L1 expression on cancer cells and ultimately producing a synergistic antitumor effect.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Review Oncology

Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma

Naoshi Nishida

Summary: Hepatocellular carcinoma is known to develop resistance to treatments due to mutations in key cellular pathways targeted by current molecular targeted agents. Immune checkpoint inhibitors show promise in cancer treatment by making cancer cells recognizable by the immune system. Understanding how cellular signaling pathways alter immune processes within tumors can help predict responses to ICI therapy in HCC cases.

CANCERS (2021)

Add to Collection
Review Oncology

Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment

Wuzhen Chen et al.

Summary: Combining antiangiogenic therapy with immunotherapy may disrupt the crosstalk between abnormal tumor vasculature and immunosuppression, increase effector immune cell infiltration, improve immunotherapy effectiveness, and reduce the risk of immune-related adverse events. This combination could serve as a potential therapeutic strategy for breast cancer treatment, promoting tumor vasculature normalization and enhancing the efficiency of immunotherapy.

BIOMARKER RESEARCH (2021)

Add to Collection
Article Medicine, Research & Experimental

Entinostat induces antitumor immune responses through immune editing of tumor neoantigens

Andrew S. Truong et al.

Summary: The study highlights the immunomodulatory effects of entinostat on tumor neoantigens, remodeling the tumor immune microenvironment, leading to a strong antitumor response with increased neoantigen-specific T cells. Combination treatment with entinostat and PD-1 blockade results in complete responses and long-term immune memory, providing a strong preclinical rationale.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection
Article Oncology

Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy

Qingyun Yuan et al.

Summary: The study developed two bispecific single-chain diabodies targeting c-Met and PD-1, showing that they inhibit tumor growth by activating T cells and enhancing the efficacy of PD-1/PD-L1 inhibitors in solid tumor immunotherapy.

ONCOIMMUNOLOGY (2021)

Add to Collection
Article Oncology

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity

Haiping Jiang et al.

Summary: IBI323, a dual blockade bispecific antibody targeting PD-L1 and LAG-3, showed superior immune stimulatory activity compared to each parent antibody in mouse models and demonstrated stronger anti-tumor activity against PD-L1/LAG-3 double knock-in mice bearing human PD-L1 knock-in tumors.

ONCOIMMUNOLOGY (2021)

Add to Collection
Meeting Abstract Oncology

Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.

Irene Brana et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection
Article Oncology

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Ronan J. Kelly et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection
Article Oncology

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Peter Schmid et al.

LANCET ONCOLOGY (2020)

Add to Collection
Article Oncology

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

Lawrence Fong et al.

CANCER DISCOVERY (2020)

Add to Collection
Article Oncology

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial

A. S. Mansfield et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection
Article Oncology

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

D. Planchard et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection
Article Oncology

TATTON: a multi-arm, phase lb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

G. R. Oxnard et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection
Article Oncology

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Kyriakos P. Papadopoulos et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection
Article Oncology

Phase Ib Study of Crizotinib Plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation

Sandip Pravin Patel et al.

ONCOLOGIST (2020)

Add to Collection
Article Oncology

Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer A Nonrandomized Controlled Trial

Salma K. Jabbour et al.

JAMA ONCOLOGY (2020)

Add to Collection
Article Multidisciplinary Sciences

Molecular mechanism of SHP2 activation by PD-1 stimulation

M. Marasco et al.

SCIENCE ADVANCES (2020)

Add to Collection
Article Immunology

Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer

Eri Sugiyama et al.

SCIENCE IMMUNOLOGY (2020)

Add to Collection
Article Oncology

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study

R. L. Ferris et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection
Article Oncology

Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy

Laura A. Vitale et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)

Add to Collection
Article Oncology

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma

Alain P. Algazi et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection
Article Gastroenterology & Hepatology

Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer

Ying Ma et al.

GASTROENTEROLOGY (2020)

Add to Collection
Article Oncology

Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma

Haijing Deng et al.

LIVER CANCER (2020)

Add to Collection
Article Oncology

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

Delvys Rodriguez-Abreu et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection
Article Oncology

A phase Ib study of abemaciclib in combination with pembrolizumab for patients (pts) with stage IV Kirsten rat sarcoma mutant (KRAS-mut) or squamous non-small cell lung cancer (NSCLC) (NCT02779751): Interim results.

Jean-Louis Pujol et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection
Article Oncology

Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study.

Martin Gutierrez et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection
Article Oncology

Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study

Steven F. Powell et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection
Review Oncology

The role of cancer-derived microRNAs in cancer immune escape

Ming Yi et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection
Review Oncology

Gene modification strategies for next-generation CAR T cells against solid cancers

Yonggui Tian et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection
Review Oncology

Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy

Chongxian Pan et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection
Article Multidisciplinary Sciences

Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma

Eugenia Zah et al.

NATURE COMMUNICATIONS (2020)

Add to Collection
Article Oncology

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Adi Diab et al.

CANCER DISCOVERY (2020)

Add to Collection
Article Oncology

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial

Luis Paz-Ares et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection
Article Immunology

4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+T Cells and Facilitates Tumor Abrogation

Qiu-xia Qu et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection
Article Oncology

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer The Canadian Cancer Trials Group CO.26 Study

Eric X. Chen et al.

JAMA ONCOLOGY (2020)

Add to Collection
Article Oncology

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial

Naiyer A. Rizvi et al.

JAMA ONCOLOGY (2020)

Add to Collection
Article Oncology

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

Lu Xie et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection
Article Oncology

Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial

Jieqiong Liu et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection
Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection
Article Biochemistry & Molecular Biology

A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade

Linlin Ma et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)

Add to Collection
Article Cell Biology

Combined antitumor effects of anti-EGFR variant III CAR-T cell therapy and PD-1 checkpoint blockade on glioblastoma in mouse model

Yujie Song et al.

CELLULAR IMMUNOLOGY (2020)

Add to Collection
Article Oncology

Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity

Alexandra Borodovsky et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection
Review Oncology

cGAS-STING, an important pathway in cancer immunotherapy

Minlin Jiang et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection
Meeting Abstract Oncology

Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study

M. Moehler et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection
Article Oncology

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Yunpeng Yang et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection
Article Biochemistry & Molecular Biology

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer

Patrick A. Ott et al.

CELL (2020)

Add to Collection
Article Cell Biology

Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy

Mengze Lv et al.

CELL RESEARCH (2020)

Add to Collection
Review Oncology

Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors

Lorenzo Galluzzi et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2020)

Add to Collection
Review Biotechnology & Applied Microbiology

RAS-targeted therapies: is the undruggable drugged?

Amanda R. Moore et al.

NATURE REVIEWS DRUG DISCOVERY (2020)

Add to Collection
Review Biochemistry & Molecular Biology

Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity

Won Suk Lee et al.

EXPERIMENTAL AND MOLECULAR MEDICINE (2020)

Add to Collection
Article Oncology

Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC

James W. Welsh et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection
Article Oncology

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Thomas Powles et al.

LANCET ONCOLOGY (2020)

Add to Collection
Article Oncology

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Thomas Powles et al.

LANCET ONCOLOGY (2020)

Add to Collection
Article Biochemistry & Molecular Biology

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Robert J. Motzer et al.

NATURE MEDICINE (2020)

Add to Collection
Article Biochemistry & Molecular Biology

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

Jianjun Gao et al.

NATURE MEDICINE (2020)

Add to Collection
Article Multidisciplinary Sciences

ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models

Amanda Hanson et al.

PLOS ONE (2020)

Add to Collection
Article Oncology

Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy

Hanzhang Zhu et al.

CELLULAR ONCOLOGY (2020)

Add to Collection
Article Oncology

Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity

Helen Kotanides et al.

CANCER IMMUNOLOGY RESEARCH (2020)

Add to Collection
Article Oncology

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial

Thomas Yau et al.

JAMA ONCOLOGY (2020)

Add to Collection
Article Medicine, General & Internal

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortes et al.

LANCET (2020)

Add to Collection
Article Medicine, General & Internal

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

Alice T. Shaw et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection
Review Oncology

Applications of gut microbiota in patients with hematopoietic stem-cell transplantation

Jifeng Yu et al.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2020)

Add to Collection
Article Cell Biology

Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule

Alexey Berezhnoy et al.

CELL REPORTS MEDICINE (2020)

Add to Collection
Review Multidisciplinary Sciences

Immune modulatory effects of oncogenic KRAS in cancer

Shaima'a Hamarsheh et al.

NATURE COMMUNICATIONS (2020)

Add to Collection
Article Medicine, Research & Experimental

CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner

Qian-Feng Zhang et al.

THERANOSTICS (2020)

Add to Collection
Article Oncology

Distinct Roles of VEGFA and ANGPT2 in Lung Adenocarcinoma and Squamous Cell Carcinoma

Shuang Qin et al.

JOURNAL OF CANCER (2020)

Add to Collection
Article Multidisciplinary Sciences

An orally available non-nucleotide STING agonist with antitumor activity

Bo-Sheng Pan et al.

SCIENCE (2020)

Add to Collection
Article Oncology

LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures

Nicolas Gestermann et al.

ONCOIMMUNOLOGY (2020)

Add to Collection
Letter Urology & Nephrology

An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis

Andrea Necchi et al.

EUROPEAN UROLOGY (2019)

Add to Collection
Article Oncology

Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer

Jessica J. Lin et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

Add to Collection
Article Oncology

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

A. J. Schoenfeld et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection
Article Oncology

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors

M. D. Hellmann et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection
Article Oncology

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours

Valentina Martin et al.

BRITISH JOURNAL OF CANCER (2019)

Add to Collection
Article Oncology

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report

James Chih-Hsin Yang et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

Add to Collection
Article Oncology

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

Vicky Makker et al.

LANCET ONCOLOGY (2019)

Add to Collection
Review Oncology

The Intersection between Tumor Angiogenesis and Immune Suppression

Osama E. Rahma et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection
Meeting Abstract Oncology

FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.

Arlene O. Siefker-Radtke et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection
Meeting Abstract Oncology

Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.

Funda Meric-Bernstam et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection
Review Oncology

Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy

Anping Li et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)

Add to Collection
Article Oncology

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West et al.

LANCET ONCOLOGY (2019)

Add to Collection
Review Biochemistry & Molecular Biology

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment

Ming Yi et al.

MOLECULAR CANCER (2019)

Add to Collection
Article Multidisciplinary Sciences

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

Elisabeth Perez-Ruiz et al.

NATURE (2019)

Add to Collection
Article Oncology

PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer

Constantia Pantelidou et al.

CANCER DISCOVERY (2019)

Add to Collection
Article Chemistry, Medicinal

Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1

Irma Herrera-Camacho et al.

EXPERT OPINION ON THERAPEUTIC PATENTS (2019)

Add to Collection
Article Oncology

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Cathy Eng et al.

LANCET ONCOLOGY (2019)

Add to Collection
Article Oncology

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial

S. Peters et al.

LUNG CANCER (2019)

Add to Collection
Article Oncology

The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity

Sangeetha Palakurthi et al.

CANCER IMMUNOLOGY RESEARCH (2019)

Add to Collection
Article Oncology

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

Panagiotis A. Konstantinopoulos et al.

JAMA ONCOLOGY (2019)

Add to Collection
Article Oncology

Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial

Eileen M. O'Reilly et al.

JAMA ONCOLOGY (2019)

Add to Collection
Article Oncology

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

David A. Schaer et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection
Article Oncology

Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma

Jiayi Yu et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection
Article Oncology

Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial

Xinan Sheng et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection
Review Oncology

Prospects for combining immune checkpoint blockade with PARP inhibition

Anping Li et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)

Add to Collection
Review Oncology

Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy

Tongyan Liu et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)

Add to Collection
Article Oncology

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial

Michael Friedlander et al.

LANCET ONCOLOGY (2019)

Add to Collection
Article Medicine, General & Internal

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection
Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

M. D. Hellmann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection
Review Oncology

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

Rachel Grosser et al.

CANCER CELL (2019)

Add to Collection
Article Medicine, General & Internal

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz-Ares et al.

LANCET (2019)

Add to Collection
Article Oncology

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Robert Motzer et al.

LANCET ONCOLOGY (2019)

Add to Collection
Review Biochemistry & Molecular Biology

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Shuang Qin et al.

MOLECULAR CANCER (2019)

Add to Collection
Article Pharmacology & Pharmacy

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade

Mingxia Zhao et al.

ACTA PHARMACEUTICA SINICA B (2019)

Add to Collection
Review Biotechnology & Applied Microbiology

Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor

Xianguang Bai et al.

ONCOTARGETS AND THERAPY (2019)

Add to Collection
Article Engineering, Biomedical

Gemcitabine nanoparticles promote antitumor immunity against melanoma

Yuan Zhang et al.

BIOMATERIALS (2019)

Add to Collection
Article Oncology

Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease

Florence T. H. Wu et al.

BRITISH JOURNAL OF CANCER (2019)

Add to Collection
Article Oncology

Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

Jianming Xu et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection
Article Oncology

A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer

Weihua Hou et al.

INVESTIGATIONAL NEW DRUGS (2019)

Add to Collection
Review Pharmacology & Pharmacy

Targeting tumor interstitial fluid pressure: will it yield novel successful therapies for solid tumors?

Lukas Clemens Boeckelmann et al.

EXPERT OPINION ON THERAPEUTIC TARGETS (2019)

Add to Collection
Article Oncology

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Bixia Tang et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)

Add to Collection
Article Oncology

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC The Phase 2 CONDOR Randomized Clinical Trial

Lillian L. Siu et al.

JAMA ONCOLOGY (2019)

Add to Collection
Article Chemistry, Multidisciplinary

A Dual-Bioresponsive Drug-Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade

Huitong Ruan et al.

ADVANCED MATERIALS (2019)

Add to Collection
Review Immunology

CTLA-4 (CD152): A versatile receptor for immune-based therapy

Holger Lingel et al.

SEMINARS IN IMMUNOLOGY (2019)

Add to Collection
Review Oncology

Advances and perspectives of PARP inhibitors

Ming Yi et al.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2019)

Add to Collection
Review Oncology

The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis

Kongju Wu et al.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2019)

Add to Collection
Review Oncology

Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy

Ming Yi et al.

INTEGRATIVE CANCER THERAPIES (2019)

Add to Collection
Article Multidisciplinary Sciences

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

V. Gopalakrishnan et al.

SCIENCE (2018)

Add to Collection
Article Multidisciplinary Sciences

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Bertrand Routy et al.

SCIENCE (2018)

Add to Collection
Article Cell Biology

Cytokines in Cancer Immunotherapy

Thomas A. Waldmann

COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)

Add to Collection
Article Oncology

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Jiehui Deng et al.

CANCER DISCOVERY (2018)

Add to Collection
Article Biophysics

Dynamic Structural Differences between Human and Mouse STING Lead to Differing Sensitivity to DMXAA

Amy Y. Shih et al.

BIOPHYSICAL JOURNAL (2018)

Add to Collection
Article Oncology

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

Frederick Arce Vargas et al.

CANCER CELL (2018)

Add to Collection
Article Oncology

Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment

Hirotake Tsukamoto et al.

CANCER RESEARCH (2018)

Add to Collection
Article Oncology

Impact of 5-Fu/oxaliplatin on mouse dendritic cells and synergetic effect with a colon cancer vaccine

Xinqiang Hong et al.

CHINESE JOURNAL OF CANCER RESEARCH (2018)

Add to Collection
Article Oncology

PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8(+) T-Cell-Driven Antitumor Immunity

Sarah L. Buchan et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection
Article Oncology

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study

Michael B. Atkins et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection
Article Oncology

MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer

Maria Saigi et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection
Article Oncology

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Julius Strauss et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection
Meeting Abstract Oncology

Late Breaking Abstract An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Y. Drew et al.

GYNECOLOGIC ONCOLOGY (2018)

Add to Collection
Article Immunology

Manganese Increases the Sensitivity of the cGAS-STING Pathway for Double-Stranded DNA and Is Required for the Host Defense against DNA Viruses

Chenguang Wang et al.

IMMUNITY (2018)

Add to Collection
Article Oncology

Dual TGF-β and PD-1 blockade synergistically enhances MAGE-A3-specific CD8+ T cell response in esophageal squamous cell carcinoma

Xinfeng Chen et al.

INTERNATIONAL JOURNAL OF CANCER (2018)

Add to Collection
Article Oncology

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

Jason J. Luke et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection
Article Oncology

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer

Michael J. Overman et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection
Meeting Abstract Oncology

A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.

Fatima Karzai et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection
Review Oncology

Gut microbiome modulates efficacy of immune checkpoint inhibitors

Ming Yi et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)

Add to Collection
Article Immunology

A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression

Jorgen Kjaergaard et al.

JOURNAL OF IMMUNOLOGY (2018)

Add to Collection
Article Oncology

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)

David R. Spigel et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

Add to Collection
Article Oncology

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients With Advanced NSCLC

A. Lisberg et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

Add to Collection
Article Oncology

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC

Scott Gettinger et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

Add to Collection
Article Oncology

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

John M. Wrangle et al.

LANCET ONCOLOGY (2018)

Add to Collection
Article Oncology

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino et al.

LANCET ONCOLOGY (2018)

Add to Collection
Review Biochemistry & Molecular Biology

The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)

Brandon Golding et al.

MOLECULAR CANCER (2018)

Add to Collection
Review Biochemistry & Molecular Biology

EGFR-TKIs resistance via EGFR-independent signaling pathways

Qian Liu et al.

MOLECULAR CANCER (2018)

Add to Collection
Article Multidisciplinary Sciences

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

Daniele V. F. Tauriello et al.

NATURE (2018)

Add to Collection
Review Oncology

Safety of combining radiotherapy with immune-checkpoint inhibition

William L. Hwang et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Add to Collection
Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection
Review Medicine, General & Internal

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Michael A. Postow et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection
Review Pharmacology & Pharmacy

Combining chemotherapy with PD-1 blockade in NSCLC

Matthen Mathew et al.

PHARMACOLOGY & THERAPEUTICS (2018)

Add to Collection
Article Multidisciplinary Sciences

The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients

Vyara Matson et al.

SCIENCE (2018)

Add to Collection
Article Cell Biology

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

Yan Lan et al.

SCIENCE TRANSLATIONAL MEDICINE (2018)

Add to Collection
Article Cell Biology

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

David A. Schaer et al.

CELL REPORTS (2018)

Add to Collection
Article Critical Care Medicine

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study

Luana Calabro et al.

LANCET RESPIRATORY MEDICINE (2018)

Add to Collection
Article Oncology

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint

Iris Koopmans et al.

ONCOIMMUNOLOGY (2018)

Add to Collection
Article Oncology

EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer

Yasuo Oshima et al.

JAMA ONCOLOGY (2018)

Add to Collection
Review Oncology

Targeting adenosine for cancer immunotherapy

Robert D. Leone et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

Add to Collection
Meeting Abstract Oncology

TOPACIO/Keynote-162: Niraparib plus pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial

Shaveta Vinayak et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection
Meeting Abstract Oncology

Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK plus advanced NSCLC (aNSCLC).

Dong-Wan Kim et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection
Meeting Abstract Oncology

Avelumab (anti-PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.

Alice Tsang Shaw et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection
Review Oncology

Abscopal effect of radiotherapy combined with immune checkpoint inhibitors

Yang Liu et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)

Add to Collection
Article Oncology

Clinical relevance of PD-L1 expression and CD8+T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer

Si-yang Liu et al.

LUNG CANCER (2018)

Add to Collection
Article Multidisciplinary Sciences

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Sanjeev Mariathasan et al.

NATURE (2018)

Add to Collection
Article Biotechnology & Applied Microbiology

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

Sarwish Rafiq et al.

NATURE BIOTECHNOLOGY (2018)

Add to Collection
Article Medicine, General & Internal

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

S. J. Antonia et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection
Article Medicine, General & Internal

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

L. Horn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection
Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer

L. Paz-Ares et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection
Article Oncology

Low-dose cyclophosphamide depletes circulating naive and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy

Lisanne Noordam et al.

ONCOIMMUNOLOGY (2018)

Add to Collection
Article Oncology

LBA15Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas

K J Harrington et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection
Article Oncology

PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients

Aung Naing et al.

CANCER CELL (2018)

Add to Collection
Review Oncology

Development of PARP and Immune-Checkpoint Inhibitor Combinations

Ross A. Stewart et al.

CANCER RESEARCH (2018)

Add to Collection
Review Biochemistry & Molecular Biology

Role of the cGAS-STING pathway in cancer development and oncotherapeutic approaches

Li Teng Khoo et al.

EMBO REPORTS (2018)

Add to Collection
Review Biochemistry & Molecular Biology

HGF/MET and the Immune System: Relevance for Cancer Immunotherapy

Federica Papaccio et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

Add to Collection
Article Multidisciplinary Sciences

Design of amidobenzimidazole STING receptor agonists with systemic activity

Joshi M. Ramanjulu et al.

NATURE (2018)

Add to Collection
Review Oncology

Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms

T. Kordbacheh et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection
Article Immunology

Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8(+) T cell dysfunction and maintain memory phenotype

Bei Wang et al.

SCIENCE IMMUNOLOGY (2018)

Add to Collection
Article Oncology

Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy

Xiaohong Wang et al.

CANCER RESEARCH (2017)

Add to Collection
Article Oncology

Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells

Naoki Horikawa et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection
Review Immunology

Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease

Joseph M. Pickard et al.

IMMUNOLOGICAL REVIEWS (2017)

Add to Collection
Review Oncology

Recent advances of highly selective CDK4/6 inhibitors in breast cancer

Hanxiao Xu et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)

Add to Collection
Review Oncology

Chimeric antigen receptor T cells: a novel therapy for solid tumors

Shengnan Yu et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)

Add to Collection
Meeting Abstract Oncology

Safety, Clinical Activity and Biomarker Results from a Phase lb Study of Erlotinib plus Atezolizumab in Advanced CrossMark NSCLC

Charles Rudin et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

Add to Collection
Article Medicine, General & Internal

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry et al.

LANCET (2017)

Add to Collection
Review Multidisciplinary Sciences

Elements of cancer immunity and the cancer-immune set point

Daniel S. Chen et al.

NATURE (2017)

Add to Collection
Article Cell Biology

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

Martina Schmittnaegel et al.

SCIENCE TRANSLATIONAL MEDICINE (2017)

Add to Collection
Article Cell Biology

Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation

Elizabeth Allen et al.

SCIENCE TRANSLATIONAL MEDICINE (2017)

Add to Collection
Article Oncology

A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer

Zu-Jun Sun et al.

ONCOTARGET (2017)

Add to Collection
Article Biochemistry & Molecular Biology

Generation and Characterization of a Bispecific Antibody Targeting Both PD-1 and c-MET

Yi Wu et al.

PROTEIN AND PEPTIDE LETTERS (2017)

Add to Collection
Review Peripheral Vascular Disease

Tumor angiogenesis and vascular normalization: alternative therapeutic targets

Claire Viallard et al.

ANGIOGENESIS (2017)

Add to Collection
Article Oncology

Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer

Robert Wesolowski et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)

Add to Collection
Article Oncology

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

Anthony W. Tolcher et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection
Article Oncology

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

Shiping Jiao et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection
Review Oncology

Prospects for combining targeted and conventional cancer therapy with immunotherapy

Philip Gotwals et al.

NATURE REVIEWS CANCER (2017)

Add to Collection
Article Oncology

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Sherene Loi et al.

CLINICAL CANCER RESEARCH (2016)

Add to Collection
Review Oncology

Combination cancer immunotherapies tailored to the tumour microenvironment

Mark J. Smyth et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2016)

Add to Collection
Article Oncology

Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients

Shaodong Hong et al.

ONCOIMMUNOLOGY (2016)

Add to Collection
Review Oncology

Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)

J. M. Kim et al.

ANNALS OF ONCOLOGY (2016)

Add to Collection
Article Oncology

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Rita Nanda et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection
Article Oncology

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

F. Stephen Hodi et al.

LANCET ONCOLOGY (2016)

Add to Collection
Article Oncology

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Corey J. Langer et al.

LANCET ONCOLOGY (2016)

Add to Collection
Article Medicine, General & Internal

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Martin Reck et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection
Review Immunology

The PD1:PD-L1/2 Pathway from Discovery to Clinical implementation

Kankana Bardhan et al.

FRONTIERS IN IMMUNOLOGY (2016)

Add to Collection
Article Oncology

Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine

Ryohei Katayama et al.

CLINICAL CANCER RESEARCH (2015)

Add to Collection
Article Biochemistry & Molecular Biology

Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression

Murugabaskar Balan et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2015)

Add to Collection
Article Immunology

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

Thibault Voron et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2015)

Add to Collection
Article Multidisciplinary Sciences

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

Christina Twyman-Saint Victor et al.

NATURE (2015)

Add to Collection
Article Medicine, General & Internal

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

R. J. Motzer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection
Article Medicine, General & Internal

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection
Article Medicine, General & Internal

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection
Article Multidisciplinary Sciences

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

Emanuela Romano et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)

Add to Collection
Article Multidisciplinary Sciences

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

Ayelet Sivan et al.

SCIENCE (2015)

Add to Collection
Article Cell Biology

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

Leticia Corrales et al.

CELL REPORTS (2015)

Add to Collection
Article Oncology

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade

David M. Woods et al.

CANCER IMMUNOLOGY RESEARCH (2015)

Add to Collection
Article Oncology

Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma

Tiansuo Zhao et al.

ONCOTARGET (2015)

Add to Collection
Article Oncology

Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8+ T cells

Joanne Y. H. Lim et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)

Add to Collection
Article Oncology

Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer

Darya Alizadeh et al.

CANCER RESEARCH (2014)

Add to Collection
Article Genetics & Heredity

DNA double-strand break repair pathway choice and cancer

Tomas Aparicio et al.

DNA REPAIR (2014)

Add to Collection
Article Medicine, Research & Experimental

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice

Liufu Deng et al.

JOURNAL OF CLINICAL INVESTIGATION (2014)

Add to Collection
Article Immunology

PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation

Muhammad Zaeem Noman et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2014)

Add to Collection
Article Virology

Cytosolic-DNA-Mediated, STING-Dependent Proinflammatory Gene Induction Necessitates Canonical NF-κB Activation through TBK1

Takayuki Abe et al.

JOURNAL OF VIROLOGY (2014)

Add to Collection
Article Multidisciplinary Sciences

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

KiBem Kim et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)

Add to Collection
Review Immunology

Immunogenic Cell Death in Cancer Therapy

Guido Kroemer et al.

ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)

Add to Collection
Article Oncology

Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo

Miki Tongu et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)

Add to Collection
Article Oncology

VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer

Magali Terme et al.

CANCER RESEARCH (2013)

Add to Collection
Article Biochemistry & Molecular Biology

Cyclic [G(2′,5′) pA(3′,5′)p] Is the Metazoan Second Messenger Produced by DNA-Activated Cyclic GMP-AMP Synthase

Pu Gao et al.

CELL (2013)

Add to Collection
Review Immunology

Oncology Meets Immunology: The Cancer-Immunity Cycle

Daniel S. Chen et al.

IMMUNITY (2013)

Add to Collection
Article Immunology

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Tyler R. Simpson et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2013)

Add to Collection
Article Immunology

Mouse, but not Human STING, Binds and Signals in Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid

Joseph Conlon et al.

JOURNAL OF IMMUNOLOGY (2013)

Add to Collection
Review Oncology

Stereotactic body radiotherapy for oligometastases

Alison C. Tree et al.

LANCET ONCOLOGY (2013)

Add to Collection
Article Multidisciplinary Sciences

cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING

Andrea Ablasser et al.

NATURE (2013)

Add to Collection
Review Immunology

STING and the innate immune response to nucleic acids in the cytosol

Dara L. Burdette et al.

NATURE IMMUNOLOGY (2013)

Add to Collection
Review Immunology

Type I interferon response and innate immune sensing of cancer

Mercedes B. Fuertes et al.

TRENDS IN IMMUNOLOGY (2013)

Add to Collection
Article Immunology

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

Tadashi Yokosuka et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2012)

Add to Collection
Review Medicine, Research & Experimental

Dual targeting strategies with bispecific antibodies

Roland E. Kontermann

MABS (2012)

Add to Collection
Article Multidisciplinary Sciences

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

Yuhui Huang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)

Add to Collection
Article Oncology

Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis

Giovanna Schiavoni et al.

CANCER RESEARCH (2011)

Add to Collection
Article Oncology

Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non-Small-Cell Lung Cancer

Primo N. Lara et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection
Article Immunology

Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion

Seth B. Coffelt et al.

JOURNAL OF IMMUNOLOGY (2011)

Add to Collection
Article Multidisciplinary Sciences

STING is a direct innate immune sensor of cyclic di-GMP

Dara L. Burdette et al.

NATURE (2011)

Add to Collection
Article Multidisciplinary Sciences

Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

Omar S. Qureshi et al.

SCIENCE (2011)

Add to Collection
Article Oncology

Angiopoietin-2 Regulates Gene Expression in TIE2-Expressing Monocytes and Augments Their Inherent Proangiogenic Functions

Seth B. Coffelt et al.

CANCER RESEARCH (2010)

Add to Collection
Article Oncology

5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity

Julie Vincent et al.

CANCER RESEARCH (2010)

Add to Collection
Article Cell Biology

Consecutive low doses of cyclophosphamide preferentially target T-regs and potentiate T cell responses induced by DNA PLG microparticle immunization

Christine M. Barbon et al.

CELLULAR IMMUNOLOGY (2010)

Add to Collection
Article Oncology

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers

Krithika N. Kodumudi et al.

CLINICAL CANCER RESEARCH (2010)

Add to Collection
Article Immunology

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

Kaori Sakuishi et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2010)

Add to Collection
Review Oncology

Clinical Development of the Anti-CTLA-4 Antibody Tremelimumab

Antoni Ribas

SEMINARS IN ONCOLOGY (2010)

Add to Collection
Article Oncology

Dual Therapeutic Efficacy of Vinblastine as a Unique Chemotherapeutic Agent Capable of Inducing Dendritic Cell Maturation

Hiroaki Tanaka et al.

CANCER RESEARCH (2009)

Add to Collection
Article Hematology

Adenosine receptors in regulation of dendritic cell differentiation and function

Sergey V. Novitskiy et al.

BLOOD (2008)

Add to Collection
Review Medicine, General & Internal

Molecular origins of cancer: Tumor angiogenesis

Robert S. Kerbel

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection
Article Biochemistry & Molecular Biology

Calreticulin exposure dictates the immunogenicity of cancer cell death

Michel Obeid et al.

NATURE MEDICINE (2007)

Add to Collection
Article Biochemistry & Molecular Biology

Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation

Je-Min Choi et al.

NATURE MEDICINE (2006)

Add to Collection
Article Immunology

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

C Zhu et al.

NATURE IMMUNOLOGY (2005)

Add to Collection
Article Biochemistry & Molecular Biology

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

RV Parry et al.

MOLECULAR AND CELLULAR BIOLOGY (2005)

Add to Collection
Article Oncology

Tie2 identifies a hematopoietic monocytes required for tumor lineage of proangiogenic vessel formation and a mesenchymal population of pericyte progenitors

M De Palma et al.

CANCER CELL (2005)

Add to Collection
Article Biochemistry & Molecular Biology

PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ

KA Sheppard et al.

FEBS LETTERS (2004)

Add to Collection
Article Oncology

An epigenetically altered tumor cell vaccine

ANH Khan et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)

Add to Collection
Review Biochemistry & Molecular Biology

Molecular regulation of vessel maturation

RK Jain

NATURE MEDICINE (2003)

Add to Collection
Review Immunology

CTLA-4: new insights into its biological function and use in tumor immunotherapy

JG Egen et al.

NATURE IMMUNOLOGY (2002)

Add to Collection
Review Cell Biology

Untangling the ErbB signalling network

Y Yarden et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)

Add to Collection
Article Immunology

Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors

WJ Magner et al.

JOURNAL OF IMMUNOLOGY (2000)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.